Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells

Hypertension

Volumn 36, Issue 3, 2000, Pages 325-329

  Ikeda, Uichi ^a   Shimpo, Masahisa ^a   Ohki, Ruri ^a   Inaba, Hideko ^a   Takahashi, Masafumi ^a   Yamamoto, Keiji ^a   Shimada, Kazuyuki ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Collagen; Extracellular matrix; Nitric oxide

Indexed keywords

COLLAGEN; COLLAGENASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; RHO FACTOR; SQUALENE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; ATHEROSCLEROSIS; COLLAGEN DEGRADATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

EID: 0033812906     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.36.3.325     Document Type: Article

References (29)

1. Type I collagen gene expression in human atherosclerosis
2. Cell proliferation and collagen synthesis are two independent events in human atherosclerotic plaques
3. Coordinated effects of fibroblast growth factor-2 on expression of fibrillar collagens, matrix metalloproteinases, and tissue inhibitors of matrix metalloproteinases by human vascular smooth muscle cells
4. Matrix metalloproteinases and cardiovascular disease
5. Molecular bases of the acute coronary syndromes
6. Matrix metalloproteinases: Implication in vascular matrix remodelling during atherogenesis
7. A definition of the intima of human arteries and of its atherosclerosis-prone regions
8. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions
9. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
10. Relationship between mevalonate pathway and arterial myocyte proliferation: In vitro studies with inhibitors of HMG-CoA reductase
11. HMG-CoA reductase inhibitors: In vivo effects on carotid intima thickening in normocholesterolemic rabbits
12. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages
13. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
14. Suppressive role of endogenous endothelial monocyte chemoattractant protein-1 on monocyte transendothelial migration in vitro
15. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis
16. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme
17. Increased expression of 72-kd type IV collagenase (MMP-2) in human atherosclerotic lesions
18. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
19. Regulation of tissue inhibitor of metalloproteinase-1 gene expression by cytokines and dexamethasone in rat hepatocyte primary cultures
20. Matrix metalloproteinases and cardiovascular disease
21. Lovastatin reduces renal vascular reactivity in spontaneously hypertensive rats
22. Geranlygeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicity
23. Relationship between mevalonate pathway and arterial myocyte proliferation: In vitro studies with inhibitors of HMG-CoA reductase
24. Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery
25. Hydrophilicity and the differential pharmacology of pravastatin
26. Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types
27. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets
28. Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: Implications for vascular protection
29. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers